Nikolas von Bubnoff

10.0k citations

138 papers · 4.1k indexed · 1 hit paper · h-index 31

Impact in

Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 61
- Chronic Myeloid Leukemia Treatments 42
- Acute Myeloid Leukemia Research 17
Genetics 56
- Chronic Lymphocytic Leukemia Research 28
- Myeloproliferative Neoplasms: Diagnosis and Treatment 25

Co-authors: Justus Duyster Christian Peschel Folker Schneller Robert Zeiser Rama Krishna Kancha Dietger Niederwieser Jürgen Finke Jeff Szer
Journals: Blood (23 papers)Leukemia (9 papers)International Journal of Molecular Sciences (7 papers)Cancers (5 papers)Journal of Clinical Oncology (5 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Nikolas von Bubnoff

129 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease 2020 · 484 citations

Peers

Countries citing papers authored by Nikolas von Bubnoff

Since Specialization

Citations

This map shows the geographic impact of Nikolas von Bubnoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nikolas von Bubnoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nikolas von Bubnoff more than expected).

Fields of papers citing papers by Nikolas von Bubnoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nikolas von Bubnoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nikolas von Bubnoff. The network helps show where Nikolas von Bubnoff may publish in the future.

Co-authors

The 25 scholars most cited alongside Nikolas von Bubnoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nikolas von Bubnoff Line = papers co-authored together Nikolas von Bubnoff links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism Blood Advances ·Axel Künstner, Vera von Kopylow, Philipp Lohneis, Matthias Kümmel, Hanno M. Witte, Lorenz Bastian, Veronica Bernard, Stephanie Stölting, Kathrin Kusch, Nikolas von Bubnoff, Konrad Steinestel, Annette Arndt, Hartmut Merz, Hauke Busch, Alfred C. Feller, Niklas Gebauer	2025	0
2	Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells Cell Communication and Signaling ·Vijay Kumar Boddu, Piet Zamzow, Mario W. Kramer, Axel S. Merseburger, Sivahari Prasad Gorantla, Matthias Klinger, Lena Cramer, Thorben Sauer, Timo Gemoll, Nikolas von Bubnoff, Frank Gieseler, Masoud Darabi	2024	3
3	Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores Cancers ·Max Kappenstein, Nikolas von Bubnoff	2024	2
4	Primary refractory plasmablastic lymphoma: A precision oncology approach Frontiers in Oncology ·Hanno M. Witte, Anke Fähnrich, Axel Künstner, Jörg Riedl, Stephanie Fliedner, Niklas Reimer, N. Hertel, Nikolas von Bubnoff, Veronica Bernard, Hartmut Merz, Hauke Busch, Alfred C. Feller, Niklas Gebauer	2023	4
5	Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs Frontiers in Cell and Developmental Biology ·Xiaoqing Xie, Pradeep Kumar Patnana, Daria Frank, Judith Schütte, Yahya Al-Matary, Axel Künstner, Hauke Busch, Helal Ahmed, Longlong Liu, Daniel R. Engel, Ulrich Dührsen, Frank Rosenbauer, Nikolas von Bubnoff, Georg Lenz, Cyrus Khandanpour	2023	3
6	Mutational Changes in Solid Cancer Cells Induce DNA Damage Repair Deficiency in Hematopoietic Cells Leading to a Distinct Spectrum of Clonal Hematopoiesis Independent from Age-Related Clonal Hematopoiesis Blood ·Theo Leitner, Axel Künstner, Michael M. Kohl, Tobias Barmwater, Helal Ahmed, Almuth Caliebe, Eva Dazert-Klebsattel, Anke Fähnrich, Stephanie Fliedner, Niklas Gebauer, Malte Spielmann, Jutta Kirfel, Verena‐Wilbeth Sailer, Lorenz Bastian, Nikolas von Bubnoff, Hauke Busch, Cyrus Khandanpour	2023	1
7	A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance Molecular Oncology ·Sivahari Prasad Gorantla, Tony Mueller, Corinna Albers, Martina Rudelius, Nikolas von Bubnoff, Justus Duyster	2023	2
8	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases International Journal of Molecular Sciences ·Carolin Czauderna, Kim Barbara Luley, Nikolas von Bubnoff, Jens U. Marquardt	2021	11
9	Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal Diagnostics ·Philipp Buechner, Marc Hinderer, Philipp Unberath, Patrick Metzger, Martin Boeker, Till Acker, Florian Haller, Elisabeth Mack, Daniel Nowak, Claudia Paret, Denny Schanze, Nikolas von Bubnoff, Sebastian Wagner, Hauke Busch, Melanie Boerries, Jan Christoph	2020	25
10	Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study Blood ·Gèrard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, Jason Butler, Eva Wagner, Édouard Forcade, Jaime Sanz, Domenico Russo, Giovanni Grillo, Tsila Zuckerman, Sinem Civriz Bozdağ, David Ritchie, Shalini Chaturvedi, Anirudh Prahallad, Karen Sinclair, Celine Wilke, Robert Zeiser	2020	2
11	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy Leukemia Research ·Nóra Rebeka Jávorniczky, Julius Wehrle, Gabriele Ihorst, Valerie Hupfer, Konrad Aumann, Dietmar Pfeifer, Christoph Niemöller, Sabine Bleul, Milena Pantić, Martin Werner, Justus Duyster, Jürgen Finke, Monika Engelhardt, Nikolas von Bubnoff, Cornelius F. Waller, Heike L. Pahl, Heiko Becker	2020	4
12	COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) Haematologica ·Frank Stegelmann, Martin Grießhammer, Markus Bangerter, Holger Hebart, Regina Reim, K. Vetter, Nikolas von Bubnoff, Christof Scheid, Ulrike Sutter, Steffen Koschmieder, Konstanze Doehner, Thomas Kindler, Andreas Reiter, Denise Wolleschak, Andreas Hochhaus, Florian H. Heidel, R. Moehle, Hartmut Doehner	2017	2
13	Ponatinib: A Third-Generation Inhibitor for the Treatment of CML Recent results in cancer research ·Julius Wehrle, Heike L. Pahl, Nikolas von Bubnoff	2014	17
14	Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA Clinical Cancer Research ·Jacqueline Maier, Thoralf Lange, Irina Kerle, Katja Specht, Melanie Bruegel, Claudia Wickenhauser, Philipp J. Jost, Dietger Niederwieser, Christian Peschel, Justus Duyster, Nikolas von Bubnoff	2013	60
15	Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment Clinical Cancer Research ·Robert C. Bauer, Jana Sänger, Christian Peschel, Justus Duyster, Nikolas von Bubnoff	2013	7
16	Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation Blood Cancer Journal ·M Sigl, Silvia Spoerl, Susanne Schnittger, Julia Meißner, Christoph Rummelt, Christian Peschel, Justus Duyster, Anthony D. Ho, Nikolas von Bubnoff	2013	4
17	FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro Cancer Research ·Nikolas von Bubnoff, Richard A. Engh, Espen Åberg, Jana Sänger, Christian Peschel, Justus Duyster	2009	89
18	Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy Clinical Cancer Research ·Rama Krishna Kancha, Nikolas von Bubnoff, Christian Peschel, Justus Duyster	2009	133
19	A Cell-Based Screening Strategy That Predicts Mutations in Oncogenic Tyrosine Kinases: Implications for Clinical Resistance in Targeted Cancer Treatment Cell Cycle ·Nikolas von Bubnoff, Simone Barwisch, Michael R. Speicher, Christian Peschel, Justus Duyster	2005	28
20	Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. PubMed ·Michael Hallek, Carola A. Neumann, Moshe Schaffer, S. Danhauser-Riedl, Nikolas von Bubnoff, Gabriele de Vos, Brian Druker, Kiyoshi Yasukawa, James D. Griffin, Bertold Emmerich	1997	63

About Nikolas von Bubnoff

Nikolas von Bubnoff is a scholar working on Hematology, Genetics, Cancer Research, Oncology and Rheumatology, having authored 138 papers that have together received 4.1k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (42 papers), Chronic Lymphocytic Leukemia Research (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers), Cancer Genomics and Diagnostics (23 papers), Eosinophilic Disorders and Syndromes (22 papers), Lymphoma Diagnosis and Treatment (19 papers), Acute Myeloid Leukemia Research (17 papers) and Viral-associated cancers and disorders (9 papers). The work is most often cited by research in Hematology (2.0k citations), Genetics (1.3k citations), Rheumatology (683 citations), Oncology (1.1k citations) and Cancer Research (537 citations). Nikolas von Bubnoff has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Justus Duyster, Christian Peschel, Folker Schneller, Robert Zeiser, Rama Krishna Kancha, Dietger Niederwieser, Jürgen Finke, Jeff Szer, Jason Butler and Celine Wilke. Their work appears in journals such as Blood, Leukemia, International Journal of Molecular Sciences, Cancers and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact